Portal de Periódicos da CAPES

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

2021; Massachusetts Medical Society; Volume: 385; Issue: 4 Linguagem: Inglês

10.1056/nejmoa2101609

1533-4406

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppé, Apolo Balyegisawa, Arvind Kaimal, Grace Mirembe, Phionah Tukamushabe, Gilbert Ategeka, James Hakim, Henry Mugerwa, Abraham Siika, Jesca Asienzo, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu,

HIV/AIDS Research and Interventions

The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine.